Michael A Laffan
Overview
Explore the profile of Michael A Laffan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mobayen G, Smith K, Ediriwickrema K, Starke R, Solomonidis E, Laffan M, et al.
J Thromb Haemost
. 2023 Apr;
21(7):1802-1812.
PMID: 37011710
Background: The von Willebrand factor (VWF) is a multimeric plasma glycoprotein essential for hemostasis, inflammation, and angiogenesis. The majority of VWF is synthesized by endothelial cells (ECs) and stored in...
2.
Laffan M, Rees S, Yadavalli M, Ferstenberg L, Shankar N, Medin J, et al.
Vaccine
. 2022 Aug;
40(38):5585-5593.
PMID: 35989136
Background: Post-marketing surveillance for COVID-19 vaccines during the pandemic identified an extremely rare thrombosis with thrombocytopenia syndrome (TTS) reported post-vaccination, requiring further characterisation to improve diagnosis and management. Methods: We...
3.
Goligher E, Bradbury C, McVerry B, Lawler P, Berger J, Gong M, et al.
N Engl J Med
. 2021 Aug;
385(9):777-789.
PMID: 34351722
Background: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with...
4.
Lawler P, Goligher E, Berger J, Neal M, McVerry B, Nicolau J, et al.
N Engl J Med
. 2021 Aug;
385(9):790-802.
PMID: 34351721
Background: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically...
5.
Turecek P, Peck R, Rangarajan S, Reilly-Stitt C, Laffan M, Kazmi R, et al.
Thromb Res
. 2021 Mar;
201:100-112.
PMID: 33662796
Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis...
6.
Mehta P, Haskard D, Laffan M, Chambers R, Hunt B
Lancet Rheumatol
. 2021 Feb;
3(3):e171-e172.
PMID: 33521654
No abstract available.
7.
Maners J, Gill D, Pankratz N, Laffan M, Wolberg A, de Maat M, et al.
Blood
. 2020 Dec;
136(26):3062-3069.
PMID: 33367543
Fibrinogen is a key component of the coagulation cascade, and variation in its circulating levels may contribute to thrombotic diseases, such as venous thromboembolism (VTE) and ischemic stroke. Gamma prime...
8.
OBrien H, Zhang X, Sanz-Hernandez M, Chion A, Shapiro S, Mobayen G, et al.
J Thromb Haemost
. 2020 Oct;
19(2):358-369.
PMID: 33075181
Background: Von Willebrand factor (VWF) contains a number of free thiols, the majority of which are located in its C-domains, and these have been shown to alter VWF function, However,...
9.
Turro E, Astle W, Megy K, Graf S, Greene D, Shamardina O, et al.
Nature
. 2020 Jun;
583(7814):96-102.
PMID: 32581362
Most patients with rare diseases do not receive a molecular diagnosis and the aetiological variants and causative genes for more than half such disorders remain to be discovered. Here we...
10.
Chan M, Hayman M, Sivapalaratnam S, Crescente M, Allan H, Edin M, et al.
Haematologica
. 2020 Apr;
106(5):1423-1432.
PMID: 32299908
We have identified a rare missense variant on chromosome 9, position 125145990 (GRCh37), in exon 8 in PTGS1 (the gene encoding cyclo-oxygenase 1, COX-1, the target of anti-thrombotic aspirin therapy)....